CompanyGraph
Recordati Industria Chimica e Farmaceutica S.p.A.
REC · Borsa Italiana · Italy
Price data from its 0KBS listing on LSE
recordati.comFinancials as of FY2025
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is $11.66B, above the global median of $1.15B
- FinancialsAltman Z-Score 3.54: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.70%Above 5Y avg (2.48%)
Annual Rate
EUR 1.42Paid semi-annual
Payout Ratio
56.3%Sustainable
Payback Period
39.3 yr
Last Ex-Dividend
May 18, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
10.08BEUR11.66B · vs all stocks (USD)
Trailing P/E
22.12xRevenue (TTM)
2.71BEUR3.13B · vs all stocks (USD)
Profit Margin
18.38%Beta
0.5310xvs all stocks
52-Week Change
0.38%vs all stocks
Forward Annual Dividend Yield
2.70%vs all stocks
Market Capitalization
10.08BEUR11.66B · vs all stocks (USD)
Enterprise Value
12.67BEUR14.67B · vs all stocks (USD)
Trailing P/E
22.12xForward P/E
13.93xPrice to Sales (TTM)
3.99xPrice to Book (MRQ)
5.06xEnterprise to Revenue
4.68xEnterprise to EBITDA
12.50xGross Margin
71.41%Profit Margin
18.38%Operating Margin
29.20%Return on Assets (TTM)
9.77%Return on Equity (TTM)
24.85%Revenue (TTM)
2.71BEUR3.13B · vs all stocks (USD)
Revenue per Share (TTM)
13.24EURUpdated Aug 19, 2026Quarterly Revenue Growth
8.30%Gross Profit (TTM)
1.93BEUR2.24B · vs all stocks (USD)
EBITDA (TTM)
1.02BEUR1.18B · vs all stocks (USD)
Net Income (TTM)
497.18MEUR575.48M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
28.00%Operating Cash Flow (TTM)
644.69MEUR746.22M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
540.97MEUR626.17M · vs all stocks (USD)
Forward Annual Dividend Rate
1.42EURUpdated Aug 19, 2026Forward Annual Dividend Yield
2.70%vs all stocks
Trailing Annual Dividend Rate
1.34EURUpdated Aug 19, 2026Trailing Annual Dividend Yield
2.55%vs all stocks
5-Year Average Dividend Yield
2.48%vs all stocks
Payout Ratio
56.30%Minority Interest (Equity)
0.00EURFY2025 · Dec 31, 2025Revenue
2.62BEURFY2025 · Dec 31, 2025Cost of Goods Sold
830.70MEURFY2025 · Dec 31, 2025Gross Profit
1.79BEURFY2025 · Dec 31, 2025Operating Income
719.74MEUR833.10M · vs all stocks (USD)
Pre-tax Income
581.27MEURFY2025 · Dec 31, 2025Income Tax Expense
137.65MEURFY2025 · Dec 31, 2025Net Income
443.62MEURFY2025 · Dec 31, 2025EBIT
680.56MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
939.26MEURFY2025 · Dec 31, 2025Research & Development
340.95MEURFY2025 · Dec 31, 2025Selling, General & Administrative
726.99MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
99.29MEURFY2025 · Dec 31, 2025EPS (Basic)
2.16EURFY2025 · Dec 31, 2025EPS (Diluted)
2.12EURFY2025 · Dec 31, 2025Basic Shares Outstanding
205.48MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
205.48MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
443.62MEURFY2025 · Dec 31, 2025Minority Interests (P&L)
0.00EURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
457.48MEURFY2025 · Dec 31, 2025Free Cash Flow
419.34MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
428.82MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
443.62MEURFY2025 · Dec 31, 2025Stock-based Compensation
16.55MEURFY2025 · Dec 31, 2025Other Non-cash Items
195.26MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-63.12MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-134.84MEURFY2025 · Dec 31, 2025Capital Expenditures
-38.13MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-45.22MEURFY2025 · Dec 31, 2025Net Acquisitions
-2.66MEURFY2025 · Dec 31, 2025Other Investing Activity
5.18MEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-35.62MEURFY2025 · Dec 31, 2025Long-term Debt Issuance
466.20MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-481.78MEURFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-118.00KEURFY2025 · Dec 31, 2025Common Stock Repurchase
-157.06MEURFY2025 · Dec 31, 2025Common Dividends Paid
-267.56MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
-395.74MEURFY2025 · Dec 31, 2025Shares Outstanding
204.81MSharesUpdated Aug 19, 2026Float Shares
101.97MSharesUpdated Aug 19, 2026% Held by Insiders
46.82%vs all stocks
% Held by Institutions
33.56%vs all stocks
Total Cash (MRQ)
391.38MEUR453.03M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.91EURUpdated Aug 19, 2026Total Debt (MRQ)
2.31BEUR2.68B · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.09xCurrent Ratio (MRQ)
1.26xBook Value per Share (MRQ)
10.40EURUpdated Aug 19, 2026Total Assets
5.25BEUR6.08B · vs all stocks (USD)
Total Current Assets
1.68BEURFY2025 · Dec 31, 2025Total Liabilities
3.33BEURFY2025 · Dec 31, 2025Total Non-current Assets
3.57BEURFY2025 · Dec 31, 2025Total Non-current Liabilities
2.28BEURFY2025 · Dec 31, 2025Total Current Liabilities
1.05BEURFY2025 · Dec 31, 2025Cash
408.95MEURFY2025 · Dec 31, 2025Cash Equivalents
19.88MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
428.82MEURFY2025 · Dec 31, 2025Accounts Receivable
570.15MEURFY2025 · Dec 31, 2025Inventory
539.80MEURFY2025 · Dec 31, 2025Accounts Payable
345.18MEURFY2025 · Dec 31, 2025Short-term Debt
337.19MEURFY2025 · Dec 31, 2025Other Current Liabilities
8.48MEURFY2025 · Dec 31, 2025Long-term Debt
2.13BEURFY2025 · Dec 31, 2025Common Stock (Book)
26.14MEURFY2025 · Dec 31, 2025Retained Earnings
2.45BEURFY2025 · Dec 31, 2025Total Shareholders' Equity
1.92BEUR2.22B · vs all stocks (USD)
Treasury Stock
239.38MEURFY2025 · Dec 31, 202552-Week Low
43.76EURUpdated Aug 19, 202652-Week High
55.15EURUpdated Aug 19, 202652-Week Change
0.38%vs all stocks
Beta
0.5310xvs all stocks
50-Day MA
51.48EURUpdated Aug 19, 2026200-Day MA
49.53EURUpdated Aug 19, 2026Avg 10-Day Volume
200.06KSharesUpdated Aug 19, 2026Avg 30-Day Volume
262.12KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
2.38EURUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.54: safe zoneNotable
Altman Z-Score: 3.54
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Market cap is $11.66B, above the global median of $1.15BNotable
Market cap (USD): 11,664,483,828.273Global Median: 1,146,734,693.424
Revenue is $3.13B, above the global median of $520.53MNotable
Revenue (USD): 3,131,407,825.92Global Median: 520,528,949.311
Levered free cash flow is $626.17M, above the global median of $16.24MNotable
Levered free cash flow (USD): 626,172,756.48Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Haisco Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CSPC Pharmaceutical Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Biomarin Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Axsome Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Insulet Corporation
Tier 1ProductionApproval-Gated PipelineRule
Cipla Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bio-Techne Corporation
Tier 1ProductionApproval-Gated PipelineFlowInterface
Sichuan Kelun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cytokinetics, Incorporated
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Tibet Gaozheng Explosive Co., Ltd.
1 interpretationMulti-Year Revenue, Profit, And Income Growth
SAP SE
1 interpretationMulti-Year Revenue, Profit, And Income Growth
Applied Industrial Technologies Inc.
1 interpretationMulti-Year Revenue, Profit, And Income Growth